Furthermore, DEHP also has toxicity on other endpoints, such as mutagenicity, immunotoxicity, cytotoxicity, and hepatotoxicity, may related to long-term chronic accumulation, whereas respiratory toxicity, skin sensitization and eye corrosion are caused mainly by short-term high-dose exposure
This is precisely why clinical trials exist: to separate real effects from belief, and to test safety as well as efficacy
Some animal studies suggest that BPC-157 can help strengthen the "tight junctions" in the gut lining, potentially reducing permeability
Disruption of this axis, by either pharmacological inhibition or genetic ablation, leads to ferroptotic cell death